London, England, United Kingdom In 1999 was created Phase4 Partners, which is appeared as VC. The main department of described VC is located in the London. The venture was found in Europe in United Kingdom.
Among the most popular fund investment industries, there are Health Care, Medical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Austria. Among the most popular portfolio startups of the fund, we may highlight Nabriva Therapeutics. Besides, a startup needs to be aged 11-15 years to get the investment from the fund.
The fund is constantly included in less than 2 investment rounds annually. Deals in the range of more than 100 millions dollars are the general things for fund. The high activity for fund was in 2015. The increased amount of exits for fund were in 2015.
The usual cause for the fund is to invest in rounds with 9 partakers. Despite the Phase4 Partners, startups are often financed by Arax Capital Partners. The meaningful sponsors for the fund in investment in the same round are Wellcome Trust, Vivo Capital, OrbiMed.
Related Funds
| Fund Name | Location |
| ACF Equity Atlantic | Canada, Halifax, Nova Scotia |
| Angelbay Holdings | - |
| Aragon Ventures | California, Menlo Park, United States |
| Ashe Partners | - |
| Beijing Zhong Jinwanwei Touzi Guanli Zhongxin (Youxian Hehuo) | Beijing, Beijing, China |
| DF International Partners | - |
| Dingju Touzi | China, Guangdong, Shenzhen |
| EasyParcel | Malaysia, Penang, Pulau Pinang |
| GreenSky Capital | Canada, Ontario, Toronto |
| JS Capital | Japan, Niigata, Niigata Prefecture |
| Micron Ventures | Boise, Idaho, United States |
| Nebraska Global | Lincoln, Nebraska, United States |
| Nest | China, Hong Kong, Hong Kong Island |
| Portfolia | California, San Mateo, United States |
| Riverside Company | New York, New York, United States |
| Sphera Corporation | Colorado, Denver, United States |
| Stanford Angels and Entrepreneurs | California, Stanford, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Avocode | $1M | 17 May 2016 | Prague, Prague, Czechia | ||
Nabriva Therapeutics | $120M | 07 Apr 2015 | Vienna |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Avocode | $1M | 17 May 2016 | Prague, Prague, Czechia | ||
Nabriva Therapeutics | $120M | 07 Apr 2015 | Vienna |
